CytRx’s INNO-206 Gets Orphan Drug Status for Soft Tissue Sarcoma

CytRx Corp.’s controlled-release treatment for soft tissue sarcomas obtained an orphan-drug designation from the U.S. Food and Drug Administration. Soft tissue sarcomas are cancers that form in the muscle, fat, fibrous tissue, blood vessels or other supporting tissue of the body.
The Wall Street Journal